In preclinical models, deacetylase inhibitors increase MHC and tumor-associated antigen expression, resulting in a decrease of competing endogenous lymphocytes and a proliferative advantage for the adoptively transferred cells[12]. This evidence concerns the gene HLA-C and neoplasm.